Cargando…
192. The Use of Area Under the Curve to Determine Therapeutic Vancomycin Dosing in Skin and Soft Tissue Infections
BACKGROUND: The vancomycin AUC/MIC target ratio of 400 to 600 mg*h/L that is recommended (level IA+) in the 2020 IDSA/ASHP vancomycin TDM guidelines is appropriate for patients with complicated MRSA infections; using lower targets for less complicated infections may reduce the risk for nephrotoxicit...
Autores principales: | Dea, Lauren, Johns, Scott T, Ma, Ariel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777332/ http://dx.doi.org/10.1093/ofid/ofaa439.502 |
Ejemplares similares
-
1329. Vancomycin Therapeutic Drug Monitoring: How to hit the Curve
por: Vala, Michael, et al.
Publicado: (2020) -
67. Agreement Among Bayesian Dosing Software for Calculating Vancomycin Area Under the Curve
por: Pineda, Ross, et al.
Publicado: (2021) -
1645. Predicting Vancomycin Area Under the Curve by Bayesian-Guided Dosing in Pediatric Patients
por: Shin, Donghyun, et al.
Publicado: (2023) -
1239. Ceftaroline versus Vancomycin as First-Line Therapy for MRSA Bacteremia
por: Kamath, Meghan, et al.
Publicado: (2021) -
Underestimation of the Calculated Area Under the Concentration-Time Curve Based on Serum Creatinine for Vancomycin Dosing
por: Jin, Sung Joon, et al.
Publicado: (2014)